• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Favorable response to erlotinib in a lung adenocarcinoma with both epidermal growth factor receptor exon 19 deletion and K-ras G13D mutations.

作者信息

Lee Chun-Nin, Chen Hsiang-Yin, Liu H Eugene

出版信息

J Clin Oncol. 2010 Mar 1;28(7):e111-2. doi: 10.1200/JCO.2009.24.0747. Epub 2009 Dec 14.

DOI:10.1200/JCO.2009.24.0747
PMID:20008635
Abstract
摘要

相似文献

1
Favorable response to erlotinib in a lung adenocarcinoma with both epidermal growth factor receptor exon 19 deletion and K-ras G13D mutations.对表皮生长因子受体第19外显子缺失和K-ras G13D突变并存的肺腺癌患者，厄洛替尼治疗反应良好。
J Clin Oncol. 2010 Mar 1;28(7):e111-2. doi: 10.1200/JCO.2009.24.0747. Epub 2009 Dec 14.
2
Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.表皮生长因子受体相关肿瘤标志物与厄洛替尼治疗非小细胞肺癌的临床结局：TRUST研究中德国中心患者的分析
J Thorac Oncol. 2008 Dec;3(12):1446-53. doi: 10.1097/JTO.0b013e31818ddcaa.
3
Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: a population-based prospective study.411例肺腺癌中表皮生长因子受体和K-RAS突变：一项基于人群的前瞻性研究。
Oncol Rep. 2009 Oct;22(4):683-91. doi: 10.3892/or_00000488.
4
[Relationship between EGFR and K-ras mutations and clinicopathological characteristics and response to erlotinib treatment in 301 Chinese patients with non-small cell lung cancer].301例中国非小细胞肺癌患者中EGFR与K-ras突变及其与临床病理特征和厄洛替尼治疗反应的关系
Zhonghua Zhong Liu Za Zhi. 2010 Sep;32(9):667-70.
5
De novo resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutation-positive patients with non-small cell lung cancer.表皮生长因子受体酪氨酸激酶抑制剂在 EGFR 突变阳性非小细胞肺癌患者中的新生耐药性。
J Thorac Oncol. 2010 Mar;5(3):399-400. doi: 10.1097/JTO.0b013e3181cee47e.
6
An uncommon insertion mutation in exon 19 of EGFR showed stable disease after TKI treatment.表皮生长因子受体（EGFR）第19外显子的一种罕见插入突变在酪氨酸激酶抑制剂（TKI）治疗后显示疾病稳定。
J Thorac Oncol. 2013 Dec;8(12):e107-8. doi: 10.1097/JTO.0b013e3182a471e0.
7
Primary and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: an update.非小细胞肺癌中表皮生长因子受体酪氨酸激酶抑制剂的原发和获得性耐药：更新。
Cancer Invest. 2012 Jun;30(5):433-46. doi: 10.3109/07357907.2012.666691.
8
Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.细支气管肺泡癌和腺癌（细支气管肺泡癌亚型）的分子特征可预测对厄洛替尼的反应。
J Clin Oncol. 2008 Mar 20;26(9):1472-8. doi: 10.1200/JCO.2007.13.0062.
9
Durable responses to Erlotinib despite KRAS mutations in two patients with metastatic lung adenocarcinoma.两名转移性肺腺癌患者尽管存在KRAS突变，但对厄洛替尼仍有持久反应。
Ann Oncol. 2010 Jun;21(6):1385-1387. doi: 10.1093/annonc/mdq153.
10
KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.KRAS突变是非小细胞肺癌中对表皮生长因子受体酪氨酸激酶抑制剂治疗耐药的重要预测指标。
Clin Cancer Res. 2007 May 15;13(10):2890-6. doi: 10.1158/1078-0432.CCR-06-3043.

引用本文的文献

1
In response to: Letter to the editor regarding 'SBRT-SG-01: final results of a prospective multicenter study on stereotactic body radiotherapy for liver metastases'.回应：致编辑的信，关于“SBRT-SG-01：立体定向体部放疗治疗肝转移瘤的前瞻性多中心研究的最终结果”
Clin Transl Oncol. 2025 Jan;27(1):400-401. doi: 10.1007/s12094-024-03671-6. Epub 2024 Sep 6.
2
Dual drive coexistence of rearrangement and mutation advanced lung adenocarcinoma and response to crizotinib.重排与突变双重驱动共存促进肺腺癌进展及对克唑替尼的反应
Transl Cancer Res. 2019 Aug;8(4):1630-1634. doi: 10.21037/tcr.2019.06.23.
3
Erlotinib versus gefitinib for brain metastases in Asian patients with exon 19 EGFR-mutant lung adenocarcinoma: a retrospective, multicenter study.
厄洛替尼对比吉非替尼用于治疗 EGFR 外显子 19 突变阳性的亚裔肺腺癌脑转移患者：一项回顾性、多中心研究。
BMC Pulm Med. 2018 Nov 20;18(1):171. doi: 10.1186/s12890-018-0734-1.
4
Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy.转移性结直肠癌抗表皮生长因子受体治疗中的预后和预测生物标志物
World J Gastroenterol. 2016 Aug 14;22(30):6944-54. doi: 10.3748/wjg.v22.i30.6944.
5
miR-134 inhibits non-small cell lung cancer growth by targeting the epidermal growth factor receptor.微小RNA-134通过靶向表皮生长因子受体抑制非小细胞肺癌生长。
J Cell Mol Med. 2016 Oct;20(10):1974-83. doi: 10.1111/jcmm.12889. Epub 2016 May 31.
6
Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer.超越KRAS：抗EGFR单克隆抗体治疗转移性结直肠癌疗效的预测因素
World J Gastroenterol. 2014 Aug 7;20(29):9732-43. doi: 10.3748/wjg.v20.i29.9732.
7
Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer.晚期结直肠癌中具有治疗靶点的预测性和预后生物标志物。
World J Gastroenterol. 2014 Apr 14;20(14):3858-74. doi: 10.3748/wjg.v20.i14.3858.
8
Parameters for individualizing systemic therapy in non-small cell lung cancer.非小细胞肺癌个体化全身治疗的相关参数。
Drug Resist Updat. 2010 Dec;13(6):196-204. doi: 10.1016/j.drup.2010.10.001. Epub 2010 Nov 3.